Aaron Thomson

Steven Silver

- bioAffinity Technologies, Inc. (BIAF) announced a **1-for-30 reverse stock split** of its common stock.  **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]** 
- The reverse stock split will become effective on **September 18, 2025, at 4:01 p.m. Eastern Time**, with trading on a split-adjusted basis commencing on **September 19, 2025** on the Nasdaq Capital Market.  **[1712762_0001493152-25-013892_ex3-1.htm:0]** **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]** 
- The primary purpose of the reverse stock split is to **comply with Nasdaq's minimum bid price requirement**.  **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]** 
- Following the split, the company will have approximately **1,338,029 shares of common stock issued and outstanding**, and stockholders will receive **cash in lieu of fractional shares**.  **[1712762_0001493152-25-013892_ex99-1.htm:0]** **[1712762_0001493152-25-013892_form8-k.htm:1]**

bioAffinity Technologies Announces 1-for-30 Reverse Stock Split

- On **September 3, 2025**, bioAffinity Technologies, Inc. announced that its **CyPath® Lung** diagnostic test was featured in **U.S. Medicine Magazine**, highlighting its potential to improve lung cancer detection and lower costs for the Department of Veterans Affairs (VA).  **[1712762_0001641172-25-026403_ex99-1.htm:0]** **[1712762_0001641172-25-026403_form8-k.htm:1]** 
- Research published in the Journal of Health Economics and Outcomes Research (JHEOR) indicated that integrating CyPath® Lung into the standard of care could have resulted in savings of nearly **$895 million for private payers** and **$379 million for Medicare** in 2022, primarily by reducing follow-up diagnostic assessments and procedures.  **[1712762_0001641172-25-026403_ex99-1.htm:0]** 
- Clinical study results demonstrated that CyPath® Lung achieved **92% sensitivity**, **87% specificity**, and **88% accuracy** in detecting lung cancer in high-risk patients with small lung nodules (less than 20 mm).  **[1712762_0001641172-25-026403_ex99-1.htm:0]** **[1712762_0001641172-25-026403_ex99-1.htm:1]**

bioAffinity Technologies (BIAF)